德国Responsif
Responsif 在癌症疫苗应用和传染性疾病疫苗研发领域提供其独家专有纳米级输运技术－NanosVir® 输运技术。
NanosVir® 输运技术的两大表现方式是：(i) 分别包含外壳蛋白、次要外壳蛋白VP1、VP2/VP3和用于蛋白质包埋的鼠类多瘤病毒的蛋白质类纳米颗粒（非感染性、不能复制、无滤过性毒菌DNA 的病毒式颗粒）和(ii) 供蛋白质/ 缩氨酸在微粒表面排列使用的单独VP1 类纳米结构载体。
在研发应用的基础上，这些纳米颗粒在酵母、大肠杆菌里以再结合方式显现出来。纳米微粒结构的制造工艺可升级、转移到环磷酸鸟苷生产设备。对于探索性项目，Responsif 可与客户签署付费服务合同，根据客户需要，为蛋白质/ 缩氨酸/ 多抗原决定基实体提供NanosVir® 输运技术。
鉴于我们拥有NanosVir® 输运技术的知识产权，我们可以与用户签署合同，建立长期业务模式（如：以专利权税为基础的模式或成立合资公司）。

With its NanosVir® delivery technology responsif offers exclusive and proprietary
nanoparticular delivery technologies for application in the field of cancer vaccines (main
activities) and in the area of vaccine development against infectious diseases.
The two main NanosVir® delivery technologies represent (i) protein-based nanoparticles
(non-infectious, non-replicating virus-like-particles w/o viral DNA) consisting of the major
and minor coat proteins VP1 and VP2/VP3, respectively, of murine polyomavirus for protein
encapsulation and (ii) solely VP1-based nanostructured carriers for protein/peptide display on
the particle surface.
Depending on the field of R&D application these nanoparticles are recombinantly expressed
in yeast or in Escherichia coli. The manufacturing process for the nanoparticulate structures
is scalable and transferable to cGMP production facilities. For exploratory projects responsif
may initially offer fee-for-service contracts for NanosVir® delivery of customer-specific
protein/peptide/multi-epitope entities. Based on our strong intellectual property position for
the NanosVir® technology such contract can be extended to long-term business models (e.g.
royalty-based models or joint-ventures).